On the Safety of the COVID-19 Convalescent Plasma Treatment: Thrombotic and Thromboembolic Concerns
Abstract
:Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Kunze, K.L.; Johnson, P.W.; van Helmond, N.; Senefeld, J.W.; Petersen, M.M.; Klassen, S.A.; Wiggins, C.C.; Klompas, A.M.; Bruno, K.A.; Mills, J.R.; et al. Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors. Nat. Commun. 2021, 12, 4864. [Google Scholar] [CrossRef]
- Joyner, M.J.; Bruno, K.A.; Klassen, S.A.; Kunze, K.L.; Johnson, P.W.; Lesser, E.R.; Wiggins, C.C.; Senefeld, J.W.; Klompas, A.M.; Hodge, D.O.; et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. In Mayo Clinic Proceedings; Elsevier: Amsterdam, The Netherlands, 2020; Volume 95, pp. 1888–1897. [Google Scholar] [CrossRef]
- Sajmi, S.; Goutham, K.; Arumugam, V.; Gopalakrishnan, N.; Lamech, T.M.; Aiswarya, D.; Krishna, R.; Vathsalyan, P.; Kannan, B.S.; Solomon, D.; et al. Efficacy and safety of convalescent plasma therapy in SARS-CoV2 patients on hemodialysis. In Hemodialysis International. International Symposium on Home Hemodialysis; John and Wiley and Sons: Hoboken, NJ, USA, 2021. [Google Scholar] [CrossRef]
- Boggiano, C.; Eisinger, R.W.; Lerner, A.M.; Anderson, J.M.; Woodcock, J.; Fauci, A.S.; Collins, F.S. Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19. Ann. Intern. Med. 2021. [Google Scholar] [CrossRef]
- Focosi, D.; Franchini, M.; Pirofski, L.A.; Burnouf, T.; Fairweather, D.; Joyner, M.J.; Casadevall, A. COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses 2021, 13, 1594. [Google Scholar] [CrossRef]
- Zhao, Q.; He, Y. Challenges of Convalescent Plasma Therapy on COVID-19. J. Clin. Virol. 2020, 127, 104358. [Google Scholar] [CrossRef]
- Siemieniuk, R.A.; Bartoszko, J.J.; Diaz Martinez, J.P.; Kum, E.; Qasim, A.; Zeraatkar, D.; Izcovich, A.; Mangala, S.; Ge, L.; Han, M.A.; et al. Antibody and cellular therapies for treatment of COVID-19: A living systematic review and network meta-analysis. BMJ 2021, 374, n2231. [Google Scholar] [CrossRef] [PubMed]
- Rojas, M.; Rodriguez, Y.; Monsalve, D.M.; Acosta-Ampudia, Y.; Camacho, B.; Gallo, J.E.; Rojas-Villarraga, A.; Ramirez-Santana, C.; Diaz-Coronado, J.C.; Manrique, R.; et al. Convalescent plasma in COVID-19: Possible mechanisms of action. Autoimmun. Rev. 2020, 19, 102554. [Google Scholar] [CrossRef]
- Aviani, J.K.; Halim, D.; Soeroto, A.Y.; Achmad, T.H.; Djuwantono, T. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics. Rev. Med. Virol. 2021, 31, e2225. [Google Scholar] [CrossRef] [PubMed]
- Greinacher, A.; Thiele, T.; Warkentin, T.E.; Weisser, K.; Kyrle, P.A.; Eichinger, S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med. 2021, 384, 2092–2101. [Google Scholar] [CrossRef] [PubMed]
- Pavord, S.; Scully, M.; Hunt, B.J.; Lester, W.; Bagot, C.; Craven, B.; Rampotas, A.; Ambler, G.; Makris, M. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis. N. Engl. J. Med. 2021, 384, 2092–2101. [Google Scholar] [CrossRef] [PubMed]
- Brodard, J.; Kremer Hovinga, J.A.; Fontana, P.; Studt, J.D.; Gruel, Y.; Greinacher, A. COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. J. Thromb. Haemost. JTH 2021, 19, 1294–1298. [Google Scholar] [CrossRef]
- Warkentin, T.E.; Kaatz, S. COVID-19 versus HIT hypercoagulability. Thromb. Res. 2020, 196, 38–51. [Google Scholar] [CrossRef] [PubMed]
- Siljander, P.R. Platelet-derived microparticles—An updated perspective. Thromb. Res. 2011, 127 (Suppl. S2), S30–S33. [Google Scholar] [CrossRef]
- Sinauridze, E.I.; Kireev, D.A.; Popenko, N.Y.; Pichugin, A.V.; Panteleev, M.A.; Krymskaya, O.V.; Ataullakhanov, F.I. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb. Haemost. 2007, 97, 425–434. [Google Scholar] [PubMed]
- Meisel, C.; Akbil, B.; Meyer, T.; Lankes, E.; Corman, V.M.; Staudacher, O.; Unterwalder, N.; Kolsch, U.; Drosten, C.; Mall, M.A.; et al. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. J. Clin. Investig. 2021, 131, e150867. [Google Scholar] [CrossRef]
- Bastard, P.; Orlova, E.; Sozaeva, L.; Levy, R.; James, A.; Schmitt, M.M.; Ochoa, S.; Kareva, M.; Rodina, Y.; Gervais, A.; et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J. Exp. Med. 2021, 218, e20210554. [Google Scholar] [CrossRef] [PubMed]
- Dotan, A.; Muller, S.; Kanduc, D.; David, P.; Halpert, G.; Shoenfeld, Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021, 20, 102792. [Google Scholar] [CrossRef]
- Shin, T.; Wada, S.; Maeyama, T.; Watanabe, S. Substance P immunoreactive nerve fibers of the canine laryngeal mucosa. Otolaryngol. Head Neck Surg. 1987, 97, 39–46. [Google Scholar] [CrossRef]
- Ziegler, C.G.K.; Miao, V.N.; Owings, A.H.; Navia, A.W.; Tang, Y.; Bromley, J.D.; Lotfy, P.; Sloan, M.; Laird, H.; Williams, H.B.; et al. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell 2021, 184, 4713–4733.e22. [Google Scholar] [CrossRef] [PubMed]
- Elrashdy, F.; Tambuwala, M.; Hassan, S.S.; Adadi, P.; Seyran, M.; Abd El-Aziz, T.M.; Rezaei, N.; Lal, A.; Aljabali, A.A.A.; Kandimalla, R.; et al. Autoimmunity roots of the thrombotic events after COVID-19 vaccination. Autoimmun. Rev. 2021; in press. [Google Scholar] [CrossRef] [PubMed]
- Sanfilippo, F.; La Rosa, V.; Astuto, M. Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma. Mayo Clin. Proc. 2021, 96, 259. [Google Scholar] [CrossRef]
- Zhu, W.; Zheng, Y.; Yu, M.; Wei, J.; Zhang, Y.; Topchyan, P.; Nguyen, C.; Janecke, R.; Kreuziger, L.B.; White, G.C.; et al. SARS-CoV-2 receptor binding domain-specific antibodies activate platelets with features resembling the pathogenic antibodies in heparin-induced thrombocytopenia. Res. Sq. 2021, rs-3. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Elrashdy, F.; Redwan, E.M.; Uversky, V.N. On the Safety of the COVID-19 Convalescent Plasma Treatment: Thrombotic and Thromboembolic Concerns. COVID 2022, 2, 1-4. https://doi.org/10.3390/covid2010001
Elrashdy F, Redwan EM, Uversky VN. On the Safety of the COVID-19 Convalescent Plasma Treatment: Thrombotic and Thromboembolic Concerns. COVID. 2022; 2(1):1-4. https://doi.org/10.3390/covid2010001
Chicago/Turabian StyleElrashdy, Fatma, Elrashdy M. Redwan, and Vladimir N. Uversky. 2022. "On the Safety of the COVID-19 Convalescent Plasma Treatment: Thrombotic and Thromboembolic Concerns" COVID 2, no. 1: 1-4. https://doi.org/10.3390/covid2010001